Shuttle Pharmaceuticals Holdings (SHPH) Long-Term Debt Issuances (2022 - 2025)
Shuttle Pharmaceuticals Holdings' (SHPH) quarterly Long-Term Debt Issuances came in at $380540.0 in Q4 2025, up 300.0% year-on-year from $95135.0 in Q4 2024, and up 220.72% quarter-over-quarter from -$315214.0 in Q3 2025.
Shuttle Pharmaceuticals Holdings (SHPH) Long-Term Debt Issuances (2022 - 2025) Analysis & Trends
Shuttle Pharmaceuticals Holdings' Long-Term Debt Issuances history runs 4 years deep, the most recent figure standing at $380540.0 for Q4 2025.
- On a quarterly basis, Long-Term Debt Issuances rose 300.0% year-over-year to $380540.0 in Q4 2025; TTM through Dec 2025 was $190270.0, a 105.53% increase from a year earlier, with the FY2025 full-year figure at $190270.0, up 218.55% from the prior year.
- Long-Term Debt Issuances improved to $380540.0 in Q4 2025 per SHPH's latest filing, from -$315214.0 in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $546244.0 in Q1 2023 and bottomed at -$3.2 million in Q4 2023.
- The 4-year median for Long-Term Debt Issuances is $62472.0 (2025), against an average of -$203751.7.
- Across the five-year window, Long-Term Debt Issuances rose 3.9% in 2023 and soared 300.0% in 2025, its largest moves.
- Year by year, Long-Term Debt Issuances stood at $822.0 in 2022, then plunged by 395419.59% to -$3.2 million in 2023, then surged by 94.14% to -$190270.0 in 2024, then surged by 300.0% to $380540.0 in 2025.
- Per Business Quant, the three latest SHPH Long-Term Debt Issuances figures stand at $380540.0 (Q4 2025), -$315214.0 (Q3 2025), and $63404.0 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 3.64 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Shuttle Pharmaceuticals Holdings | 120,186.04 | 120,186.04 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 380,540.00 |
| Dec 31, 2025 | 380,540.00 |
| Sep 30, 2025 | -315,214.00 |
| Sep 30, 2025 | -315,214.00 |
| Jun 30, 2025 | 63,404.00 |
| Jun 30, 2025 | 63,404.00 |
| Mar 31, 2025 | 61,540.00 |
| Mar 31, 2025 | 61,540.00 |
| Dec 31, 2024 | -190,270.00 |
| Dec 31, 2024 | -190,270.00 |
| Dec 31, 2023 | -3.25 Mn |
| Dec 31, 2023 | -3.25 Mn |
| Jun 30, 2023 | 139,229.00 |
| Jun 30, 2023 | 139,229.00 |
| Mar 31, 2023 | 546,244.00 |
| Mar 31, 2023 | 546,244.00 |
| Sep 30, 2022 | 822.00 |
| Sep 30, 2022 | 822.00 |
| Mar 31, 2022 | 525,715.00 |
| Mar 31, 2022 | 525,715.00 |